Related Experiment Video
Updated: Jun 2, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Why does quick-release bromocriptine decrease cardiac events?
1University of Alabama-Birmingham, Southside Endocrinology, Birmingham, AL 35205, USA. dshbell@yahoo.com
Diabetes, Obesity & Metabolism
|May 17, 2011
Summary
Quick-release bromocriptine significantly reduced cardiovascular events by 40% in type 2 diabetes patients. This may be due to improved insulin sensitivity and reduced metabolic risk factors, offering a novel therapeutic approach.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Type 2 diabetes is associated with increased cardiovascular risk.
- Insulin resistance is a key factor in type 2 diabetes pathogenesis and cardiovascular complications.
- Current treatments for type 2 diabetes do not fully address cardiovascular risk.
Purpose of the Study:
- To evaluate the cardiovascular safety and efficacy of quick-release bromocriptine in patients with type 2 diabetes.
- To investigate the potential mechanisms by which bromocriptine may reduce cardiovascular events.
Main Methods:
- A placebo-controlled, prospective safety study.
- Inclusion of patients diagnosed with type 2 diabetes.
- Administration of quick-release bromocriptine or placebo.
Main Results:
- A 40% reduction in cardiovascular events was observed in the bromocriptine group compared to placebo.
- Potential mechanisms include re-establishment of diurnal variation, decreased insulin resistance, and reduced activity of sympathetic and renin-angiotensin systems.
- Lowered insulin resistance leads to decreased hepatic glucose production, improved glucose uptake, and reduced levels of postprandial glucose, free fatty acids, and triglycerides.
Conclusions:
- Quick-release bromocriptine demonstrates a significant reduction in cardiovascular events in type 2 diabetes patients.
- The therapeutic effect is likely mediated by improved insulin sensitivity and associated metabolic benefits.
- Bromocriptine represents a promising therapeutic option for managing cardiovascular risk in type 2 diabetes.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:14Decreased pulse rate
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...